Hands4U: Prevention of hand eczema among health care workers.

Hands4U: A multifaceted strategy to implement guideline-based recommendations to prevent hand eczema in health care workers.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON21321

Enrollment

3000

Registered

2011-03-16

Start date

2011-04-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hand eczema

Interventions

The randomisation to the intervention group or the control group takes place on the level of the departments of the participating hospitals to avoid contamination. The control group will receive a le

Eligibility

Inclusion criteria

Inclusion criteria: We include participants who: 1. Are at risk for developing hand eczema; 2. Are able to fill out Dutch questionnaires; 3. Are employed at one of the participating hospitals; 4. Are 18 -65 years old.

Exclusion criteria

Exclusion criteria: We exclude particpants who: 1. Work less than 8 hours a week.

Design outcomes

Primary

Measure	Time frame
Hand eczema will be measured using the NOSQ-2002 questions D1, D2 and D5 (Flyvholm et al, 2002; Susitaival et al, 2003).	—

Secondary

Measure	Time frame
1. Symptoms of hand eczema are measured by a questionnaire derived from the NVAB guideline which was validated by Smit et al (1992); 2. The actual use of preventive measures is measured with a modified version of section E of the Nordic Occupational Skin Questionnaire (NOSQ-2002) (Flyvholm et al, 2002; Susitaival et al, 2003). In addition purchase data is used; 3. ASE determinants (attitude, social influence, self-efficacy and intention) will be measured by questions based on questionnaires from Driessen et al (2008) and Vyth et al (2011); 4. Disease specific quality of life is measured using the Dutch version of the DLQI (Evers et al, 2009); 5. Workers' global assesment of the health of their hands and patients’ global assessment of eczema will be assessed, using a Visual Analogue Scale (VAS) from the NOSQ-2002 (Flyvholm et al, 2002; Susitaival et al, 2003); 6. Data on sickness absence and reduced work productivity due to hand eczema will be collected in the questionnaires by using the PRODISQ (Koopmanschap et al, 2005) and the WHO-HPQ (Kessler et al, 2003; Kessler et al, 2004); 7. Psychosocial work characteristics will be measured by means of a Dutch version of Karasek's Job Content Questionnaire containing the constructs: decision authority and co-worker support (Karasek et al, 1998).	—

Measure

Time frame

1. Symptoms of hand eczema are measured by a questionnaire derived from the NVAB guideline which was validated by Smit et al (1992); 2. The actual use of preventive measures is measured with a modified version of section E of the Nordic Occupational Skin Questionnaire (NOSQ-2002) (Flyvholm et al, 2002; Susitaival et al, 2003). In addition purchase data is used; 3. ASE determinants (attitude, social influence, self-efficacy and intention) will be measured by questions based on questionnaires from Driessen et al (2008) and Vyth et al (2011); 4. Disease specific quality of life is measured using the Dutch version of the DLQI (Evers et al, 2009); 5. Workers' global assesment of the health of their hands and patients’ global assessment of eczema will be assessed, using a Visual Analogue Scale (VAS) from the NOSQ-2002 (Flyvholm et al, 2002; Susitaival et al, 2003); 6. Data on sickness absence and reduced work productivity due to hand eczema will be collected in the questionnaires by using the PRODISQ (Koopmanschap et al, 2005) and the WHO-HPQ (Kessler et al, 2003; Kessler et al, 2004); 7. Psychosocial work characteristics will be measured by means of a Dutch version of Karasek's Job Content Questionnaire containing the constructs: decision authority and co-worker support (Karasek et al, 1998).

—

Contacts

Public ContactCecile R.L. Boot

Van der Boechorststraat 7 - room BS7-C573

crl.boot@vumc.nl+31 (0)20 4449680

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)